Latest disclosed round
Series B
- Date
- 2024-07-01
- Amount
- USD 170m
- Sector
- Biotech & techbio
- Companies House
- 14426488
Series B
Beacon Therapeutics
Gene therapy (ophthalmology)
VerifiedSeries BLondon (dual HQ with Cambridge, Massachusetts, US - verify UK-HQ eligibility before use)
Evidence status
Directory ready
- Identity
- Verified
- Match
- Verified
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
6 linked investors
Funding record
1 disclosed round
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2024-07-01 | Series B | $170M | Forbion, Syncona, Oxford Science Enterprises, University of Oxford, TCGX, Advent Life Sciences |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.